Wesana Health focuses on developing psychedelic-assisted and naturally sourced treatments, including psilocybin-based medicine, to address neurological and psychological harms from traumatic brain injury. The company emphasizes evidence-based formulations and protocols developed through clinical research and academic partnerships. Proceeds from its recent financing will primarily fund preclinical and clinical development of its therapies and enable expansion of its senior leadership team. Wesana positioned the financing ahead of a planned go-public transaction via a reverse takeover. The company highlights patient empowerment and advancing alternative treatments for TBI as core mission priorities. No operating metrics (revenue or user figures) were disclosed in the announcement. Wesana Health is an emerging life sciences company committed to patient empowerment and the advancement of psilocybin-based medicine to improve health and wellness. The company champions development and delivery of psychedelic and naturally-sourced therapies to treat traumatic brain injury (TBI). Through extensive clinical research and academic partnerships, Wesana is developing evidence-based formulations and protocols to help patients overcome neurological, psychological and mental health ailments caused by trauma. The company announced the close of a $4 million convertible note financing round led by The Conscious Fund and Ambria Capital. Wesana positions itself around evidence-based approaches and academic collaborations as it advances its therapeutic programs. The financing reflects a capital event reported by the company to support its ongoing development activities.

Total raised

$17M

Funding rounds

2

Latest round

Equity

Latest activity

Mar 2021